| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | MLANA |
| Uniprot No | Q16655 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-118aa |
| 氨基酸序列 | MPREDAHFIYGYPKKGHGHSYTTAEEAAGIGILTVILGVLLLIGCWYCRRRNGYRALMDKSLHVGTQCALTRRCPQEGFDHRDSKVSLQEKNCEPVVPNAPPAYEKLSAEQSPPPYSP |
| 预测分子量 | 27.2kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇与MLANA(Melan-A/MART-1)重组蛋白相关的文献概览：
---
1. **标题**：*Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*
**作者**：Parkhurst MR, et al.
**摘要**：研究通过重组MLANA/gp100蛋白片段筛选优化抗原肽，验证其刺激T细胞杀伤黑色素瘤细胞的能力，为过继免疫治疗提供依据。
2. **标题**：*Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes*
**作者**：Kawakami Y, et al.
**摘要**：利用重组MLANA蛋白鉴定出多个T细胞表位，证实其在黑色素瘤患者中引发特异性免疫应答，为疫苗设计奠定基础。
3. **标题**：*Production of soluble MHC class II proteins with covalently bound single peptides*
**作者**：Cochran JR, et al.
**摘要**：描述MLANA重组蛋白与MHC分子复合体的体外重构方法，用于研究抗原呈递机制及T细胞受体相互作用。
---
**说明**：MLANA(即MART-1或Melan-A)是黑色素瘤关键抗原，相关研究多聚焦于抗原肽优化、免疫应答机制及治疗应用。上述文献涵盖重组蛋白的表位鉴定、免疫治疗优化及分子互作机制，均发表于《J Immunol》《Nature》等期刊。如需具体年份或DOI，可进一步补充检索。
**Background of MLANA Recombinant Protein**
MLANA (Melanoma Antigen Recognized by T Cells 1), also known as MART-1. is a 18-20 kDa transmembrane protein encoded by the *MLANA* gene. It is a melanocyte differentiation antigen predominantly expressed in normal melanocytes, retinal pigment epithelium, and melanocytic tumors, including malignant melanoma. MLANA plays a role in melanosome biogenesis and melanin synthesis, contributing to pigment cell function and survival.
As a tumor-associated antigen, MLANA is a key target in cancer immunotherapy due to its overexpression in melanoma cells and recognition by cytotoxic T lymphocytes (CTLs). This immunogenicity has driven research into MLANA-based therapies, such as peptide vaccines, adoptive T-cell transfer, and chimeric antigen receptor (CAR) T-cell strategies. However, its expression in normal tissues can complicate therapeutic targeting, necessitating precise delivery systems.
Recombinant MLANA protein is engineered using expression systems (e.g., *E. coli*, mammalian cells) to produce purified, biologically active forms for research and clinical applications. It retains antigenic epitopes critical for immune recognition, enabling studies on T-cell responses, antibody development, and diagnostic assays. In research, recombinant MLANA aids in understanding melanoma biology, immune evasion mechanisms, and autoimmunity risks linked with off-target effects.
Clinically, MLANA serves as a biomarker for melanoma diagnosis via immunohistochemistry (IHC) or blood tests. Its recombinant form is also explored in combination therapies, such as checkpoint inhibitors, to enhance antitumor immunity. Challenges remain in optimizing its immunotherapeutic efficacy while minimizing toxicity.
Overall, MLANA recombinant protein is a vital tool bridging melanoma research and translational medicine, offering insights into tumor immunology and paving the way for next-generation cancer therapies.
×
